

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of the Claims:

Claims 1-9. (canceled without prejudice)

10. (currently amended) A method of treating idiopathic pulmonary fibrosis which comprises administering to a patient having idiopathic pulmonary fibrosis a therapeutically effective amount of thalidomide, or a pharmaceutically acceptable salt, ~~selvate~~ or stereoisomer thereof.

11. (previously presented) The method of claim 10, which further comprises administering a therapeutically effective amount of a second active agent.

12-13. canceled.

14. (currently amended) The method of claim 10, wherein said thalidomide is administered in an amount of 50-2,000 mg per day.

15. (currently amended) The method of claim 14, wherein said thalidomide is administered in an amount of 50-1,000 mg per day.

16. (currently amended) The method of claim 15, wherein said thalidomide is administered in an amount of 50-800 mg per day.

17. (currently amended) The method of claim 16, wherein said thalidomide is administered in an amount of 200-800 mg per day.

18. (currently amended) The method of claim 16, wherein said thalidomide is administered in an amount of 50 mg, 100 mg, 200 mg, 300 mg or 400 mg per day.

19. (previously presented) The method of claim 10, wherein said thalidomide is in a dosage form for oral, mucosal, parenteral, topical, transdermal or transcutaneous administration to the patient.

20. (previously presented) The method of claim 19, wherein said dosage form is selected from tablets, caplets, capsules, cachets, troches, lozenges, dispersions, suppositories, powders, aerosols, gels, liquid, eye drops or sterile solids.

21. (previously presented) The method of claim 11, wherein said second active agent is in an amount of 1-1,000 mg.

22. (previously presented) The method of claim 21, wherein said second active agent is in an amount of 5-500 mg.

23. (previously presented) The method of claim 22, wherein said second active agent is in an amount of 10-350 mg.

24. (previously presented) The method of claim 23, wherein said second active agent is in an amount of 50-200 mg.